학술논문
Efficacy and safety of novel topical pigment-correcting regimen with biweekly diamond tip microdermabrasion procedures on facial hyperpigmentation.
Document Type
Academic Journal
Author
Goberdhan L; Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.; Schneider K; Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.; Makino ET; Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.; Bautista A; Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.; Mehta RC; Allergan Aesthetics, an AbbVie Company, Irvine, California, USA.
Source
Publisher: Blackwell Science Country of Publication: England NLM ID: 101130964 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-2165 (Electronic) Linking ISSN: 14732130 NLM ISO Abbreviation: J Cosmet Dermatol Subsets: MEDLINE
Subject
Language
English
Abstract
Background: Facial hyperpigmentation can negatively affect an individual's emotional and psychosocial well-being.
Aims: Assess safety and tolerability of a combination of microdermabrasion (DG) procedures using a novel brightening pro-infusion serum (EC-DG) with a targeted at-home treatment regimen in subjects with mild to severe facial hyperpigmentation, including melasma, post-inflammatory hyperpigmentation, and dark spots.
Patients/methods: This 12-week, open-label study enrolled 18 subjects (Fitzpatrick skin types I-IV) who underwent 6 in-office DG procedures with EC-DG (one procedure administered biweekly), along with daily topical application of a brightening treatment serum and dark spot cream. End points included change from baseline across multiple skin quality attributes and the Melasma Area and Severity Index (MASI), self-assessment questionnaires, and tolerability assessments.
Results: The combination treatment was well tolerated and resulted in significant (p ≤ 0.05) improvements from baseline in radiance, tactile roughness, and moisturization/hydration immediately after the first treatment, in MASI score at day 3, and in overall hyperpigmentation at week 4. Most (94.1%) subjects were satisfied with treatment.
Conclusions: DG procedures using EC-DG combined with a targeted at-home skincare regimen are effective and tolerable for treating facial hyperpigmentation across a broad range of skin types.
(© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)
Aims: Assess safety and tolerability of a combination of microdermabrasion (DG) procedures using a novel brightening pro-infusion serum (EC-DG) with a targeted at-home treatment regimen in subjects with mild to severe facial hyperpigmentation, including melasma, post-inflammatory hyperpigmentation, and dark spots.
Patients/methods: This 12-week, open-label study enrolled 18 subjects (Fitzpatrick skin types I-IV) who underwent 6 in-office DG procedures with EC-DG (one procedure administered biweekly), along with daily topical application of a brightening treatment serum and dark spot cream. End points included change from baseline across multiple skin quality attributes and the Melasma Area and Severity Index (MASI), self-assessment questionnaires, and tolerability assessments.
Results: The combination treatment was well tolerated and resulted in significant (p ≤ 0.05) improvements from baseline in radiance, tactile roughness, and moisturization/hydration immediately after the first treatment, in MASI score at day 3, and in overall hyperpigmentation at week 4. Most (94.1%) subjects were satisfied with treatment.
Conclusions: DG procedures using EC-DG combined with a targeted at-home skincare regimen are effective and tolerable for treating facial hyperpigmentation across a broad range of skin types.
(© 2024 The Authors. Journal of Cosmetic Dermatology published by Wiley Periodicals LLC.)